Clinical Trials Browser

ebselen × Clear all

NCT01451853 2017-09-25

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Phase 2 Unknown

Head & NeckThoracic

Ototoxicity, Deafness, Head and Neck Neoplasms, Lung Neoplasms, Tinnitus, Hearing Loss

NCT01452607 2016-06-29

Study to Evaluate the Safety and Pharmacokinetics of SPI-1005

Phase 1 Completed

Neoplasms, Hearing Loss